<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>44</patient-age><report-id>PHFR2012GB005483</report-id><gender>female</gender><reactions><reaction>Urinary tract infection</reaction><reaction>Profuse watery diarrhea,5-6 episodes per day</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>CLOZARIL</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>CEPHALEXIN</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Delusional disorder, unspecified type</indication></indications><outcomes/><country>United Kingdom</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053162_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134147</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>PHFR2012GB005483</safetyreportid>
		<primarysourcecountry>GB</primarysourcecountry>
		<occurcountry>GB</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-10</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="2">No</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-10-17</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-06</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHFR2012GB005483</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportergivename>Saman`</reportergivename>
			<reporterfamilyname>Shahzad</reporterfamilyname>
			<reporterstreet>Aston house,26 village road,Oxton,Wirral</reporterstreet>
			<reporterpostcode>CH4355R</reporterpostcode>
			<reportercountry>GB</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
		</primarysource>
		<primarysource>
			<reportertitle>Dr</reportertitle>
			<reportergivename>John</reportergivename>
			<reporterfamilyname>Franklin</reporterfamilyname>
			<reporterorganization>Ashton House Hospital</reporterorganization>
			<reporterstreet>26 Village Road</reporterstreet>
			<reportercity>Prenton</reportercity>
			<reporterstate>Merseyside</reporterstate>
			<reporterpostcode>CH43 5SR</reporterpostcode>
			<reportercountry>GB</reportercountry>
			<qualification code="1">Physician</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>AP</patientinitial>
			<patientinvestigationnumb>657693</patientinvestigationnumb>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19671114</patientbirthdate>
			<patientsex code="2">Female</patientsex>
			<reaction>
				<primarysourcereaction>Urinary tract infection</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Urinary tract infection</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Urinary tract infection</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Profuse watery diarrhea,5-6 episodes per day</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Diarrhoea</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Diarrhoea</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121026</reactionstartdate>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20121119</reactionenddate>
				<reactionduration>25</reactionduration>
				<reactiondurationunit>804</reactiondurationunit>
				<reactionfirsttime>60</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121105</testdate>
				<testname>Stool analysis</testname>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>CLOZARIL</medicinalproduct>
				<obtaindrugcountry>GB</obtaindrugcountry>
				<drugauthorizationnumb>19-758</drugauthorizationnumb>
				<drugauthorizationcountry>GB</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>300</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>300 mg daily</drugdosagetext>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Delusional disorder, unspecified type</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-08-28</drugstartdate>
				<actiondrug code="2">Dose Reduced</actiondrug>
				<activesubstance>
					<activesubstancename>CLOZAPINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Diarrhoea</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Diarrhoea</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Urinary tract infection</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Urinary tract infection</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>CLOZARIL</medicinalproduct>
				<obtaindrugcountry>GB</obtaindrugcountry>
				<drugauthorizationnumb>19-758</drugauthorizationnumb>
				<drugauthorizationcountry>GB</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugdosagetext>UNK UKN, dose reduced</drugdosagetext>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<actiondrug code="2">Dose Reduced</actiondrug>
				<activesubstance>
					<activesubstancename>CLOZAPINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Diarrhoea</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Diarrhoea</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Urinary tract infection</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Urinary tract infection</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>CEPHALEXIN</medicinalproduct>
				<obtaindrugcountry>GB</obtaindrugcountry>
				<drugauthorizationcountry>GB</drugauthorizationcountry>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>CEFALEXIN</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHFR2012GB005483, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report received from a <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>on 17 Oct 2012 with follow up report received from <Semaphore x="2009300" class="Occupation" value="Health Care Professional" score="1.00" ID="C53287">health care professional </Semaphore>on 06 Dec 2012. This case refers to <Semaphore x="2102861" class="Occupation" value="Legal Occupations" score="1.00" ID="C97637">adult </Semaphore>female patient (CPMS no. 657693). The patient concomitant medication included Cephelexin. The patient received <Semaphore x="385527" class="Medicine" value="Clozaril" score="0.74" ID="247865">Clozaril </Semaphore>(<Semaphore x="385490" class="Medicine" value="Clozapine" score="0.49" ID="252210">clozapine</Semaphore>) tablet <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>for <Semaphore x="1840071" class="Disease or Finding" value="Delusional Disorder" score="1.00" ID="C94379">delusional disorder </Semaphore>at 300mg daily dose from 28 Aug 2012. On an unknown date, the patient had <Semaphore x="2672555" class="Disease or Finding" value="Urinary Tract Infection" score="1.00" ID="C50791">urinary tract infection </Semaphore>(<Semaphore x="2672555" class="Disease or Finding" value="Urinary Tract Infection" score="1.00" ID="C50791">UTI</Semaphore>). On 26 Oct 2012 the patient <Semaphore x="2004277" class="Procedure" value="Have Diarrhea" score="1.00" ID="C104300">had profuse <Semaphore x="2906722" class="MedDRA LLT" value="Diarrhoea" score="1.00" ID="10012735">watery diarrhea</Semaphore></Semaphore>, 5-6 episodes per day. Stool examination did not showed any <Semaphore x="3033151" class="MedDRA LLT" value="Infection" score="1.00" ID="10021789">infection</Semaphore>. <Semaphore x="1847734" class="Disease or Finding" value="Diarrhea" score="1.00" ID="C2987">Diarrhea </Semaphore>recovered on 19 Nov 2012 after reduction in dose of <Semaphore x="385527" class="Medicine" value="Clozaril" score="0.74" ID="247865">Clozaril</Semaphore>. <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">Treatment </Semaphore>with suspect <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug </Semaphore>was ongoing with <Semaphore x="1863467" class="Procedure" value="Dose Reduced" score="1.00" ID="C49505">reduced dose</Semaphore>. Seriousness of the events was not reported. <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">Outcome </Semaphore>of the event <Semaphore x="1847734" class="Disease or Finding" value="Diarrhea" score="1.00" ID="C2987">diarrhea </Semaphore>was reported as <Semaphore x="1803876" class="Disease or Finding" value="Complete Recovery" score="1.00" ID="C82467">complete recovery </Semaphore>while it was not reported for other event. Causality of the event <Semaphore x="1847734" class="Disease or Finding" value="Diarrhea" score="1.00" ID="C2987">diarrhea </Semaphore>was reported as suspected while it was not reported for other event.Follow up report received from <Semaphore x="2009300" class="Occupation" value="Health Care Professional" score="1.00" ID="C53287">health care professional </Semaphore>on 06 Dec 2012: Updated <Semaphore x="2091429" class="Disease or Finding" value="Laboratory Test Result" score="1.00" ID="C36292">lab </Semaphore>data, suspect <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug </Semaphore>info (indication, action taken and dose) and added event (<Semaphore x="1847734" class="Disease or Finding" value="Diarrhea" score="1.00" ID="C2987">diarrhea</Semaphore>).</narrativeincludeclinical>
				<sendercomment>Based on Review of available reported data does not allow for a proper causality assessment. Reported event is unassessable.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>